hydroxychloroquine has been researched along with Brain Ischemia in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the present study was to determine the neuroprotective effects of hydroxychloroquine (HCQ) and the timing of its administration in cerebral ischemia/reperfusion (I/R) in rats." | 8.31 | Pre-treatment or post-treatment with hydroxychloroquine demonstrates neuroprotective effects in cerebral ischemia/reperfusion. ( Babataheri, S; Malekinejad, H; Mosarrezaii, A; Soraya, H, 2023) |
| " The aim of the present study was to determine the neuroprotective effects of hydroxychloroquine (HCQ) and the timing of its administration in cerebral ischemia/reperfusion (I/R) in rats." | 4.31 | Pre-treatment or post-treatment with hydroxychloroquine demonstrates neuroprotective effects in cerebral ischemia/reperfusion. ( Babataheri, S; Malekinejad, H; Mosarrezaii, A; Soraya, H, 2023) |
| "To investigate whether hydroxychloroquine treatment is associated with major adverse cardiovascular events (MACE) (myocardial infarction, ischemic stroke, or cardiovascular-associated death) in patients with cutaneous LE (CLE) or systemic LE (SLE)." | 4.02 | Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study. ( Dreyer, L; Egeberg, A; Gislason, G; Haugaard, JH; Kofoed, K; Ottosen, MB, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Babataheri, S | 3 |
| Malekinejad, H | 3 |
| Mosarrezaii, A | 3 |
| Soraya, H | 3 |
| Haugaard, JH | 1 |
| Dreyer, L | 1 |
| Ottosen, MB | 1 |
| Gislason, G | 1 |
| Kofoed, K | 1 |
| Egeberg, A | 1 |
2 other studies available for hydroxychloroquine and Brain Ischemia
| Article | Year |
|---|---|
Pre-treatment or post-treatment with hydroxychloroquine demonstrates neuroprotective effects in cerebral ischemia/reperfusion.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Brain Ischemia; Hydroxychloroquine; Infarction; N | 2023 |
Pre-treatment or post-treatment with hydroxychloroquine demonstrates neuroprotective effects in cerebral ischemia/reperfusion.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Brain Ischemia; Hydroxychloroquine; Infarction; N | 2023 |
Pre-treatment or post-treatment with hydroxychloroquine demonstrates neuroprotective effects in cerebral ischemia/reperfusion.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Brain Ischemia; Hydroxychloroquine; Infarction; N | 2023 |
Pre-treatment or post-treatment with hydroxychloroquine demonstrates neuroprotective effects in cerebral ischemia/reperfusion.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Brain Ischemia; Hydroxychloroquine; Infarction; N | 2023 |
Pre-treatment or post-treatment with hydroxychloroquine demonstrates neuroprotective effects in cerebral ischemia/reperfusion.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Brain Ischemia; Hydroxychloroquine; Infarction; N | 2023 |
Pre-treatment or post-treatment with hydroxychloroquine demonstrates neuroprotective effects in cerebral ischemia/reperfusion.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Brain Ischemia; Hydroxychloroquine; Infarction; N | 2023 |
Pre-treatment or post-treatment with hydroxychloroquine demonstrates neuroprotective effects in cerebral ischemia/reperfusion.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Brain Ischemia; Hydroxychloroquine; Infarction; N | 2023 |
Pre-treatment or post-treatment with hydroxychloroquine demonstrates neuroprotective effects in cerebral ischemia/reperfusion.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Brain Ischemia; Hydroxychloroquine; Infarction; N | 2023 |
Pre-treatment or post-treatment with hydroxychloroquine demonstrates neuroprotective effects in cerebral ischemia/reperfusion.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Brain Ischemia; Hydroxychloroquine; Infarction; N | 2023 |
Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study.
Topics: Adult; Brain Ischemia; Cardiovascular Diseases; Cohort Studies; Comorbidity; Confounding Factors, Ep | 2021 |